If you have spent any time researching ketamine therapy, you have probably encountered conflicting information. Some of it is outdated. Some of it confuses recreational use with clinical treatment. And some of it reflects genuine concerns that deserve a thoughtful, honest answer.
We understand why these myths persist. Many of them are rooted in real experiences or partial truths that have been taken out of context. Our goal here is not to dismiss the concerns behind them, but to provide the full picture so you can make an informed decision about your care. We have written previously about the safety profile of ketamine therapy and how the FDA views ketamine. This article goes further, addressing the specific misconceptions we hear most often.
"Ketamine Is Just a Party Drug or a Horse Tranquilizer"
This is perhaps the most persistent ketamine misconception, and it is understandable why people believe it. Ketamine does appear in recreational contexts, and it is used in veterinary medicine. But describing it as "just" a party drug or a horse tranquilizer ignores the vast majority of its medical history.
Ketamine was first synthesized in 1962 and received FDA approval as an anesthetic in 1970. It has been used in operating rooms, emergency departments, burn units, and field hospitals for more than fifty years. It is on the World Health Organization's List of Essential Medicines, a designation reserved for medications considered most critical to a functioning health system. It is used in every emergency room in the United States.
The recreational context represents a small fraction of how ketamine has been used throughout its history. Judging a medication by its misuse rather than its clinical record would be like dismissing morphine, benzodiazepines, or dozens of other medications that have both medical value and potential for recreational misuse.
"Ketamine Therapy Is Experimental and Unproven"
The word "experimental" implies that we are still guessing. We are not. Ketamine has been the subject of thousands of peer-reviewed studies spanning decades. The evidence base is substantial and continues to grow.
Research suggests that ketamine achieves a 70% or higher response rate for treatment-resistant depression — meaning patients who have not responded to traditional antidepressants. A Cleveland Clinic study involving more than 1,000 patients demonstrated significant improvement in chronic pain outcomes. Harvard Medical School comparison studies have examined ketamine alongside other treatment modalities and found meaningful clinical benefit.
It is true that much of ketamine's use for mental health and pain is considered "off-label," meaning the FDA has not specifically approved it for those indications. But off-label does not mean experimental. Off-label prescribing is a routine, well-established part of medicine. Many widely used medications are prescribed off-label based on strong clinical evidence. For a more detailed discussion, see our article on the FDA and ketamine.
"You Will Get Addicted to Ketamine"
This concern is understandable, especially for patients who have struggled with other substances or who have been cautious about any medication with psychoactive properties. We take it seriously, and it is part of what we screen for before treatment begins.
That said, clinical IV ketamine therapy is fundamentally different from recreational use. Here is why:
- Controlled dosing. The doses used in clinical settings are carefully calibrated — typically sub-anesthetic — and administered by a CRNA who monitors the entire session
- No take-home prescriptions. Patients do not leave with ketamine. Every dose is administered in the clinic under direct supervision
- Structured protocol. Treatment follows a defined schedule with clear clinical endpoints, not open-ended or on-demand use
- Screening protocols. We evaluate each patient's history, including any history of substance use, before beginning treatment
Published research suggests that the addiction risk at therapeutic doses in a supervised clinical setting is very low. The patterns associated with ketamine dependence in the literature involve chronic, high-dose, unsupervised recreational use — a context that bears little resemblance to what happens in a clinical environment.
"Ketamine Is a One-Time Fix"
We understand the appeal of this idea. When someone has been suffering for months or years, the hope for a single treatment that resolves everything is natural. But setting that expectation would not be honest.
Most patients benefit from an initial protocol of approximately six sessions over two to three weeks. This series helps establish the neurobiological changes that ketamine facilitates. After the initial protocol, maintenance sessions are typically scheduled at longer intervals — monthly, or sometimes less frequently — based on individual response.
What makes ketamine particularly valuable is not that it "fixes" everything in one sitting, but that it opens what researchers describe as a neuroplastic window — a period of heightened brain flexibility during which new neural connections can form more readily. What you do around that window matters. Therapy, lifestyle changes, integration work, and follow-through all play a role in determining how lasting the benefits become.
Ketamine creates an opportunity. It is what patients do with that opportunity — the therapy, the reflection, the changes — that determines the long-term outcome. — Marla Peterson, CRNA, Music City Ketamine
For more on what a realistic treatment timeline looks like, we have written about how the process works.
"The Experience Is Scary or Hallucinogenic"
This myth often comes from media portrayals or secondhand accounts of high-dose recreational use. The clinical experience at therapeutic doses is quite different from what most people imagine.
The majority of our patients describe the experience as deeply relaxing. Common descriptions include:
- A mild, dreamlike state — not vivid hallucinations, but a soft alteration of awareness
- Altered time perception — sessions may feel shorter or longer than their actual duration
- A sense of deep physical relaxation, sometimes described as floating
- Emotional openness — some patients find that thoughts or memories surface gently during the session
At Music City Ketamine, we take the environment seriously. Marla Peterson, CRNA, monitors your vitals throughout the entire session. We provide weighted blankets, soft music, and a calm, private setting. Walter and Wilma, our therapy dogs, are part of the clinic environment as well — their presence is something many patients mention as unexpectedly comforting.
"Dreamlike, not frightening" is how most patients describe it. If you want to know more about what to expect, read our guide to your first ketamine infusion.
"Any Doctor Can Administer Ketamine Safely"
This is not so much a myth as a dangerous oversimplification. Technically, any licensed physician can prescribe ketamine. But the ability to prescribe a medication and the training to administer it safely during an IV infusion are two very different things.
Provider qualifications matter enormously. Not all ketamine clinics offer the same level of clinical oversight, and the differences can be significant. Here is what to look for:
- Anesthesia training. A CRNA (Certified Registered Nurse Anesthetist) has doctorate-level training in anesthesia, including airway management, hemodynamic monitoring, and pharmacology. This is the level of expertise required to manage the physiological effects of ketamine safely
- Real-time monitoring. Hospital-grade monitoring of blood pressure, heart rate, oxygen saturation, and other vitals should be standard — not optional
- Emergency preparedness. If a rare adverse reaction occurs, the provider needs the skills and equipment to respond immediately. Anesthesia-trained providers are uniquely qualified for this
At Music City Ketamine, every infusion is administered and monitored by Marla Peterson, CRNA, who has more than 20 years of anesthesia experience. We see one patient at a time. This is a deliberate choice that reflects how we believe ketamine therapy should be delivered.
"Ketamine Only Works for Depression"
Depression, particularly treatment-resistant depression, is where much of the early ketamine research focused. But the evidence has expanded considerably. Research now supports the therapeutic use of ketamine for a range of conditions:
- Anxiety disorders — including generalized anxiety and social anxiety
- PTSD — research suggests ketamine may help reduce the intensity of traumatic memories and associated symptoms
- OCD — some studies indicate rapid reduction in obsessive-compulsive symptoms following ketamine treatment
- Chronic pain — including CRPS (complex regional pain syndrome), fibromyalgia, neuropathy, and migraines. A Cleveland Clinic study with over 1,000 patients showed meaningful pain reduction
- Suicidal ideation — one of the most striking findings in the literature is ketamine's ability to reduce suicidal thinking within hours, far faster than traditional medications
- Addiction — emerging research suggests ketamine may support recovery from alcohol and opioid use disorders
The reason ketamine appears to help across such a range of conditions has to do with its mechanism of action. Rather than targeting a single neurotransmitter system the way most antidepressants do, ketamine works through NMDA receptors and glutamate signaling, promoting neuroplasticity — the brain's ability to form new connections and pathways. This broader mechanism may explain why it affects multiple conditions that share underlying neural circuit disruption.
We have written dedicated articles on ketamine for safety, how the process works, and specific conditions. If one of these resonates with your situation, we are happy to discuss it further.